Products & ServicesEvent: September 2, 2026
DELFI Diagnostics built a program called LungMATCH for patients to navigate lung cancer treatment, biomarker testing, and clinical trials.
Published
Signal category
Products & Services
Quote
“GO2 for Lung Cancer built a program for exactly that moment, called LungMATCH.”
— DELFI Diagnostics team
Company
DELFI Diagnostics
DELFI's AI and whole-genome sequencing platform powers FirstLook Lung, a blood-based lung cancer screening test.
- Industry
- Medical and Diagnostic Laboratories
- Location
- Palo Alto, US
- Company size
- 151 employees
DELFI uses AI, machine learning and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Founded 2019